BACKGROUNDSupply and License Agreement • April 2nd, 2010 • Casey Container Corp • Metal mining • New Mexico
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • June 10th, 2005 • Hemosense Inc • Surgical & medical instruments & apparatus • Massachusetts
This Supply and License Agreement (“Agreement”) is made and entered into this 5th day of March, 1999, by and between Dade Behring Inc., (“Dade Behring”) a Delaware corporation with a principal place of business at 1717 Deerfield Road, Deerfield, Illinois 60015 and HemoSense, Inc., a Delaware corporation (“HemoSense”) having a principal place of business at 2157 O’Toole Avenue, Suite H, San Jose, California.
SUPPLY and LICENSE AGREEMENTSupply and License Agreement • November 5th, 2012 • Singulex Inc • Services-medical laboratories • California
This Supply and License Agreement (the “AGREEMENT”) is by and between MOLECULAR PROBES, INC. (“MPI”), an Oregon corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402, INVITROGEN IP HOLDINGS, INC., a Delaware corporation with offices at 1600 Faraday Avenue, Carlsbad, California 92008 (“IIPH”), and SINGULEX, INC. (“SINGULEX”), a Delaware corporation, with a principal business address at 4041 Forest Park Avenue, St. Louis, Missouri 63108, and is effective as of June 12, 2006 (the “EFFECTIVE DATE”).
SUPPLY AND LICENSE AGREEMENT BETWEENSupply and License Agreement • July 20th, 2021
This Supply and License Agreement (the “Agreement”) is entered into and made effective as of July 30, 2020 (the “Effective Date”), by and between Serum Institute of India Private Limited., an Indian company having its principal place of business at 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028 (“SIIPL”, which expression shall, unless repugnant to the context thereof, mean and include its successors and permitted assigns), and Novavax, Inc., a Delaware, USA corporation having its principal place of business at 21 Firstfield Road, Gaithersburg, MD 20878 USA (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates). Novavax and SIIPL may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Amendment No. 1 to the Supply and License AgreementSupply and License Agreement • June 5th, 2024 • Golden Arrow Merger Corp. • Industrial organic chemicals
This Amendment No. 1 to Supply and License Agreement (this “Amendment”) is made as of 8/19/2022 between Bolt Threads, Inc., a Delaware corporation (“Bolt”), and Vegamour, Inc., a Delaware corporation (“Vegamour”) (together, the “Parties”).
SUPPLY AND LICENSE AGREEMENT BETWEEN GEMA Biotech S.A. San Vladimiro 3056, San Isidro, Province of Buenos Aires, Argentina AND Serendex ApS CVR 3053 2228 Slotsmarken 12,1 2970 Horsholm DenmarkSupply and License Agreement • March 13th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations
[***] Indicates that information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
EXHIBIT 10 C.I. = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. SUPPLY AND...Supply and License Agreement • August 7th, 2007 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations
EX-10.21 16 g05278a3exv10w21.htm EX-10.21 SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • May 5th, 2020 • New York
NOTE: Portions of this exhibit indicated by [*] are subject to a confidential treatment request, and have been omitted from this exhibit. Complete, unredacted copies of this exhibit have been filed with the Securities and Exchange Commission as part of the Company’s confidential treatment request. SUPPLY AND LICENSE AGREEMENT This Supply and License Agreement (“Agreement”) is made and entered into as of this 7th day of June, 2007 (the “Effective Date”), by and between BioLife Solutions, Inc. (“BioLife”), and Bioheart, Inc. (“Customer”). RECITALS The parties desire to enter into an agreement pursuant to which (i) BioLife shall supply Customer with all its requirements for BioLife Products (as defined below) to Customer, (ii) Customer shall purchase all its requirements for BioLife Products from BioLife, and (iii) BioLife shall place certain of its proprietary technology and know how into escrow, and agree to grant Customer a license to use such technology and know how in the event a Rel
AMENDMENT NO. 5 TO THE SUPPLY AND LICENSE AGREEMENT BY AND BETWEEN HESKA CORPORATION ANDSupply and License Agreement • May 10th, 2016 • Heska Corp • Biological products, (no disgnostic substances)
This AMENDMENT NO. 5, dated as of this 30th day of October, 2015 (“Amendment No. 5”), to the Supply and License Agreement, dated as of August 1, 2003 (as amended from time to time and hereinafter collectively referred to as the “Agreement”), is made by and between INTERVET INC., d/b/a MERCK ANIMAL HEALTH (“MAH”), and HESKA CORPORATION (“Heska”).
EX-10.4 6 d938337dex104.htm SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** Note:...Supply and License Agreement • May 5th, 2020 • Delaware
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • February 8th, 2024 • Solidion Technology Inc. • Miscellaneous electrical machinery, equipment & supplies • Delaware
This Supply and License Agreement (this “Agreement”) is made by and between Global Graphene Group, Inc., a Delaware corporation (“G3”), Angstron Materials, Inc., an Ohio corporation (“AMI”), and Honeycomb Battery Company, an Ohio corporation (“Customer”), and is effective as of February 2, 2024 (the “Effective Date”). G3, AMI and Customer are sometimes collectively referred to hereafter as the “Parties” and each individually as a “Party”.
EX-10.02 3 dex1002.htm SUPPLY AND LICENSE AGREEMENT SUPPLY AND LICENSE AGREEMENT (INTERNATIONAL TERRITORIES)Supply and License Agreement • May 5th, 2020 • Utah
This Agreement is made effective as of April 9, 2007 by and between Colloral LLC, a Delaware limited liability company (“Colloral”), and Futurebiotics, LLC, a New York limited liability company (“Futurebiotics, LLC”).
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • August 19th, 2024 • Bolt Projects Holdings, Inc. • Industrial organic chemicals • California
This Supply and License Agreement (this “Agreement”), dated as of August 1, 2021 (the “Effective Date”), is by and between Bolt Threads, Inc., a Delaware corporation (“Bolt”), and VEGAMOUR, Inc., a Delaware corporation (“VEGAMOUR”) (each a “Party” and, collectively, the “Parties”).
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • March 30th, 2007 • Heska Corp • Biological products, (no disgnostic substances) • Delaware
This Agreement is entered into on 1 August 2003 (“Effective Date”), by and between Heska Corporation, a Delaware corporation, having a principal place of business at 1613 Prospect Parkway, Fort Collins, Colorado 80525 (“Heska”) and Schering-Plough Animal Health Corporation, a Delaware corporation, having a place of business at 1095 Morris Avenue, Union, New Jersey 07083-1982 (“Schering”).
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • August 13th, 2009 • Lectec Corp /Mn/ • Electromedical & electrotherapeutic apparatus • Minnesota
THIS SUPPLY AND LICENSE AGREEMENT (“Agreement”) entered into as of January 1, 2004 (the “Effective Date”) by and between NOVARTIS CONSUMER HEALTH, INC., 200 Kimball Drive, Parsippany, NJ 07054, a Delaware corporation (“Novartis”) and LECTEC CORPORATION, 10701 Red Circle Drive, Minnetonka, MN 55343, a Minnesota corporation (“LecTec”).
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • February 5th, 2009 • Transcept Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Supply and License Agreement (hereinafter referred to as “Agreement”), effective as of the 27th day of June, 2006 (the “Effective Date”), is made by and between SPI Pharma, Inc., a Delaware corporation with its principal offices at 321 Cherry Lane, New Castle, Delaware 19720 (hereinafter referred to as “Supplier”) and TransOral Pharmaceuticals, Inc., a Delaware corporation with its principal offices at 1003 W. Cutting Blvd., Suite 110, Pt. Richmond, California 94804 (hereinafter referred to as “Purchaser”). Purchaser and Supplier are sometimes referred to herein individually as a “Party” or collectively as the “Parties”.
AMENDMENT #2 TO SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • November 16th, 2009 • Transcept Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Amendment #2 (hereinafter referred to as this “Amendment”), dated as of the 30th day of July, 2009 (the “Amendment Date”), is made by and between SPI Pharma, Inc., a Delaware corporation with its principal offices at Rockwood Office Park, 503 Carr Road, Wilmington, Delaware 19809 (hereinafter referred to as “Supplier”), and Pivot Acquisition, Inc., a Delaware corporation formerly known as Transcept Pharmaceuticals, Inc. (hereinafter referred to as “Purchaser”) and a wholly-owned subsidiary of Transcept Pharmaceuticals, Inc. (a publicly-traded Delaware corporation hereinafter referred to as “Transcept”) with its principal offices at 1003 W. Cutting Blvd., Suite 110, Pt. Richmond, California 94804. Purchaser and Supplier are sometimes referred to herein individually as a “Party” or collectively as the “Parties”.
AGREEMENTSupply and License Agreement • March 7th, 2019 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
AMENDMENT NO 3 TO SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • November 14th, 2013 • Heska Corp • Biological products, (no disgnostic substances)
This Amendment No. 3 is entered into as of July 30th, 2013 by and between Heska Corporation, a Delaware corporation, having a principal place of business at 3760 Rocky Mountain Avenue, Loveland, CO 80538 ("Heska") and Intervet Inc., d/b/a Merck Animal Health a Delaware corporation, having a place of business at 556 Morris Avenue, Summit, New Jersey 07901-1330 ("Merck").
CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Amendment to SUPPLY AND LICENSE AGREEMENT DATED 30 JULY 2020 (“Agreement”)...Supply and License Agreement • November 10th, 2020 • Novavax Inc • Biological products, (no disgnostic substances)
This Amendment (“Amendment”) to the SUPPLY AND LICENSE AGREEMENT dated July 30, 2020 (“Agreement”), is entered into between Novavax, Inc., a Delaware, USA corporation having its principal place of business at 21 Firstfield Road, Gaithersburg, MD 20878 USA (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates) and Serum Institute of India Private Limited, a company incorporated under the Companies Act, 1956 with registration number U80903PN1984PTC03294, and having its registered address as 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028 (“SIIPL”, which expression shall, unless repugnant to the context thereof, mean and include its successors and permitted assigns), and is entered into and made effective as of September 11, 2020 (“Effective Date of Amendment”). All capitalized terms or otherwise undefined terms herein this Amendment shall have the same meaning and interpretation as in the Agreement
ContractSupply and License Agreement • March 31st, 2014 • Heska Corp • Biological products, (no disgnostic substances)
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • November 3rd, 2011 • Efactor Holdings Inc • Nevada
This SOFTWARE SUPPLY AND LIECNSE AGREEMENT (“Agreement”) is effective as of the 9th day of September, 2011 (“the Effective Date”) between Triton Distribution Systems, Inc., having offices at 105 Barbaree Way, Tiburon, CA 94920 (“Triton”); and EFactor Holdings, Inc. ("EHI"), having offices at 105 Barbaree Way, Tiburon, CA 94920.
Supply and licence agreement for DITR Data ServicesSupply and License Agreement • June 29th, 2021
March 6, 2014 Mr. Nick Virca President and CEO, HedgePath Pharmaceuticals, Inc. nvirca@hedgepathpharma.com Dear Nick: Amendment No. 2 to Supply and License AgreementSupply and License Agreement • March 11th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research
We refer to the supply and license agreement dated, September 3, 2013, between Mayne Pharma International Pty Ltd and HedgePath Pharmaceuticals, Inc., as amended (Agreement). For due and valuable consideration, the receipt and sufficiency of which each party acknowledges, and in accordance with clause 26.8 of the Agreement, the parties agree to amend the Agreement, as set out below.
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • February 6th, 2008 • Cti Industries Corp • Fabricated rubber products, nec • Wisconsin
As and when requested by Johnson in writing, Supplier shall promptly provide Johnson with all information necessary for Johnson to comply with all legal and regulatory requirements relating to the Products or any products in which the Products are to be incorporated, including, without limitation, the registration, packaging, labeling and provision of safety information (e.g., material safety data sheet) in all countries where products incorporating the Products are sold from time to time. Johnson may disclose such information as required by applicable law.
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • March 31st, 2005 • Heska Corp • Biological products, (no disgnostic substances) • Delaware
This Agreement is entered into on 1 August 2003 ("Effective Date"), by and between Heska Corporation, a Delaware corporation, having a principal place of business at 1613 Prospect Parkway, Fort Collins, Colorado 80525 ("Heska") and Schering-Plough Animal Health Corporation, a Delaware corporation, having a place of business at 1095 Morris Avenue, Union, New Jersey 07083-1982 ("Schering").
AMENDMENT NO. 1 TO SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • March 16th, 2009 • Heska Corp • Biological products, (no disgnostic substances)
This Amendment No. 1 modifies the Supply and License Agreement between Heska Corporation and Schering-Plough Animal Health Corporation, dated August 1, 2003 (“Original Agreement”).
Mr. Nick Virca President and CEO, HedgePath Pharmaceuticals, Inc. nvirca@hedgepathpharma.com Dear Nick: Amendment No. 1 to Supply and License AgreementSupply and License Agreement • December 23rd, 2013 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research
We refer to the supply and license agreement dated, September 3, 2013, between Mayne Pharma International Pty Ltd and HedgePath Pharmaceuticals, Inc. (Agreement). For due and valuable consideration, the receipt and sufficiency of which each party acknowledges, and in accordance with clause 26.8 of the Agreement, the parties agree to amend the Agreement, as set out below.
Supply and License AgreementSupply and License Agreement • March 31st, 2021 • Triangle Canna Corp. • Agricultural production-crops • California
This Supply Agreement (“Agreement”) is entered into as of March 15, 2021 (“Effective Date”), by and between Bar X Farms LLC, a California limited liability company (“Purchaser”), and Humboldt Standard LLC, a California limited liability company (“Supplier”). Supplier and Purchaser are each referred to herein as a “Party” and, collectively, the “Parties.”
AMENDMENT NO. 6 TO THE SUPPLY AND LICENSE AGREEMENT BY AND BETWEEN HESKA CORPORATION AND INTERVET INC., d/b/a MERCK ANIMAL HEALTHSupply and License Agreement • March 9th, 2018 • Heska Corp • Biological products, (no disgnostic substances)
This AMENDMENT NO. 6, dated as of this 27th day of November, 2017 ("Amendment No. 6"), to the Supply and License Agreement, dated as of August 1, 2003, as amended by that certain Amendment No.1, dated as of August 31, 2005; that certain Amendment No. 2, dated as of December 7, 2011; that certain Amendment No. 3, dated as of July 30, 2013; that certain Amendment No. 4 dated as of December 9, 2013; that certain Amendment No. 5 dated as of October 30, 2015; and that certain Letter Agreement dated as of August 14, 2015 (collectively, the "Agreement"), is made by and between INTERVET INC., d/b/a MERCK ANIMAL HEALTH ("MAH"), and HESKA CORPORATION ("Heska").
EXHIBIT 10.20 ------------- LETTER AGREEMENT ---------------- 1. BACKGROUND ---------- a. Isolyser Company, Inc., a Georgia corporation, having its principal place of business at 4320 International Blvd., Norcross, Georgia 30093 ("Isolyser"), and...Supply and License Agreement • April 2nd, 2001 • Isolyser Co Inc /Ga/ • Orthopedic, prosthetic & surgical appliances & supplies
AMENDMENT #1 TO SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • February 5th, 2009 • Transcept Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment #1 (this “Amendment #1”), effective as of March 14, 2008 (the “Effective Date”), is made by and between SPI Pharma, Inc., a Delaware corporation with its principal offices at 321 Cherry Lane, New Castle, Delaware 19720 (hereinafter referred to as “Supplier”) and Transcept Pharmaceuticals, Inc. (formerly, TransOral Pharmaceuticals), a Delaware corporation with its principal offices at 1003 W. Cutting Blvd., Suite 110, Pt. Richmond, California 94804. SPI and the Transcept may be referred to herein by name or as a “Party,” or collectively as the “Parties.”
Supply and License AgreementSupply and License Agreement • May 21st, 2020 • Pure Bioscience, Inc. • Miscellaneous chemical products • California
This SUPPLY AND LICENSE AGREEMENT (this “Agreement”) is entered into as of May 1, 2020 (“Effective Date”) by and between Pure Bioscience, Inc., a Delaware corporation with its principal place of business at 9669 Hermosa Avenue, Rancho Cucamonga, CA 91730, hereinafter (“Supplier” or “PURE” or “Pure”), and Packers Sanitation Services, Inc., an Ohio corporation with its principal place of business at 3681 Prism Lane, Kieler, WI 53812, hereinafter (“Licensee”), each referred to as “Party” and collectively as “Parties.”
Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** NOTE: CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO CERTAIN PORTIONS HEREOF DENOTED WITH “[***]” AMENDMENT NO. 2...Supply and License Agreement • January 11th, 2018 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
THIS AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT AND AMENDMENT NO. 1 TO SUBLICENSE AGREEENT (the “Amendment”), effective as of January 10, 2018 (the “Effective Date”), is made by and among:
Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***”Supply and License Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
